======= CPA4 =======
== Gene Information ==
* **Official Symbol**: CPA4
* **Official Name**: carboxypeptidase A4
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=51200|51200]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9UI42|Q9UI42]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=CPA4&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20CPA4|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/607635|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene is a member of the carboxypeptidase A/B subfamily, and it is located in a cluster with three other family members on chromosome 7. Carboxypeptidases are zinc-containing exopeptidases that catalyze the release of carboxy-terminal amino acids, and are synthesized as zymogens that are activated by proteolytic cleavage. This gene could be involved in the histone hyperacetylation pathway. It is imprinted and may be a strong candidate gene for prostate cancer aggressiveness. [provided by RefSeq, Jul 2008].
* **UniProt Summary**: Metalloprotease that could be involved in the histone hyperacetylation pathway (PubMed:10383164). Releases a C-terminal amino acid, with preference for -Phe, -Leu, -Ile, -Met, -Tyr and -Val (PubMed:20385563). {ECO:0000269|PubMed:10383164, ECO:0000269|PubMed:20385563}.
|Peptidase M14|
|Propep M14|
|metallocarboxypeptidase activity|
|histone acetylation|
|internal peptidyl-lysine acetylation|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|protein acetylation|
|protein acylation|
|peptidyl-lysine modification|
|histone modification|
|covalent chromatin modification|
|cellular component|
|chromatin organization|
|zinc ion binding|
|peptidyl-amino acid modification|
|chromosome organization|
|proteolysis|
|extracellular space|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp281|Disulfiram 4.3μM R06 exp281]]|-1.95|
|[[:results:exp286|HMS-I2 1μM R06 exp286]]|-1.89|
|[[:results:exp122|Golgicide-A 4μM R03 exp122]]|-1.87|
|[[:results:exp493|IL-3 9ng/ml R08 exp493]]|-1.86|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM on day4 R07 exp420]]|1.76|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 8983
* **Expression level (log2 read counts)**: 1.4
{{:chemogenomics:nalm6 dist.png?nolink |}}